ARF6 and pulmonary arterial hypertension: Inhibition of Arf6 activity with cytohesin inhibitors, such as SecinH3, restores BMPRII expression and reduces inflammatory responses in cultured endothelial cells and the lungs of animal models of pulmonary hypertension and prevents development of the disease in preclinical models of PAH.